Jacquie Ross, Vice President, Investor Relations at Gilead Sciences Thank you, Rebecca. Just after market closed today, we ...

Q3 2024 Earnings Call Nov 06, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that ...

Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Gilead Sciences (GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from its COVID revenues and spurring investor anticipation for new products ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...

(Operator Instructions) I'll now hand the call over to Jacquie Ross, Vice President of Investor Relations and Corporate ... section of our website at gilead.com. The speakers on today’s call ...